

Studienverzeichnis Medizinische Onkologie

Mammakarzinom, Gynäkologie

Studie	Phase	Indikation / Beschreibung	PI	Offen seit
SAKK 21/12	II	Transdermal CR1447 (4-OH-testosterone) in endocrine responsive-HER2 negative and triple negative-androgen receptor positive metastatic or locally advanced breast cancer	S.Aebi	01/17
SAKK 24/14	II	Anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative EGFR positive breast cancer	R.Winterhalder	09/16
SAKK 25/14	II	Eribulin as 1st line treatment in elderly patients (≥ 70 years) with advanced breast cancer	S.Aebi	Q3/15
SAKK 96/12	III	Prevention of Symptomatic Skeletal Events with Denosumab Administered every 4 Weeks versus every 12 Weeks	R.Winterhalder	03/15
PALLAS	III	Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+ / HER2-negative early breast cancer	S.Aebi	04/17
IBCSG AURORA		Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer	S.Aebi	04/16
Pfizer B9991010	III	Avelumab in Combination with and/or Following Chemotherapy in patients with Previously Untreated Epithelial Ovarian Cancer	S.Aebi	06/17

Lunge

Studie	Phase	Indikation / Beschreibung	PI	Offen seit
ETOP Splendour	III	Addition of denosumab to standard first-line anticancer treatment in advanced NSCLC	O.Gautschi	02/15
PEARLS EORTC	III	Pembrolizumab versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy	O.Gautschi	02/16
AbbVie MERU	III	Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage SCLC	O.Gautschi	07/17
NEOLung		Non-randomized performance evaluation study assessing the molecular diagnostic tests NEOliquid and NEOplus in lung-cancer patients	O.Gautschi	05/17
SAKK 16/14	II	Anti-PD-L1 antibody MEDI4736 in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) NSCLC	O.Gautschi	03/15

Gastrointestinale Tumoren

Studie	Phase	Indikation / Beschreibung	PI	Offen seit
SAKK 41/13	III	Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients	R.Winterhalder	04/16
SAKK 41/14	III	Physical activity program in patients with metastatic colorectal cancer who receive palliative first-line chemotherapy	R.Winterhalder	02/16
SAKK 41/16	I/II	Neoadjuvant treatment with Regorafenib and Capecitabine combined with radiotherapy in locally advanced rectal cancer	R.Winterhalder	04/16
SAKK PRODIGE	II	Systematic surgery vs. monitoring and salvage surgery in operable oesophageal cancer in complete clinical response after chemoradiation	R.Winterhalder	06/17
PhenoTox	II	Hunting the missing heritability of early-onset fluoropyrimidine-related toxicity in cancer patients	S.Aebi	01/17
Eli Lilly JVDD PASS	IV	Safety and Effectiveness of Ramucirumab in Patients with advanced Gastric Cancer	R.Winterhalder	02/17

Urologische Tumoren

Studie	Phase	Indikation / Beschreibung	PI	Offen seit
SAKK 63/12		Prospective cohort study with collection of clinical data and serum of patients with prostate disease	A.Mattei	10/14
SAKK 96/12	III	Prevention of Symptomatic Skeletal Events with Denosumab Administered every 4 Weeks versus every 12 Weeks	R.Winterhalder	03/15
SAKK 08/14	III	Metformin in patients with castration resistant prostate cancer in combination with Enzalutamide vs. Enzalutamide alone	R.Winterhalder	04/16
KSSG PRO-PLAT	II	Carboplatin in patients with metastatic castration-resistant prostate cancer (CRPC) and PTEN-loss and/or DNA repair defects	B.Müller	02/16
SAG- TCCS		Swiss Austrian German Testicular Cancer Cohort Study	B.Müller	02/15
Roche M029983	II	Atezolizumab in locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract	R.Riklin	05/17

Lymphome und Myelom

Studie	Phase	Indikation / Beschreibung	PI	Offen seit
SAKK 36/13	II	Combination of ibrutinib and bortezomib followed by ibrutinib maintenance to treat patients with relapsed and refractory mantle cell lymphoma	T.Zander	08/15
SAKK 35/14	II	Rituximab with or without Ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy	T.Zander	Q4/15

Diverse

Studie	Phase	Indikation / Beschreibung	PI	Offen seit
SENS		A structured early palliative care intervention for patients with advanced cancer – a randomized controlled trial with a nested qualitative study	B. Müller	02/15